SEKISUI-HOUSE
30.11.2021 15:02:59 CET | Business Wire | Press release
Sekisui House, Ltd. (TOKYO:1928) has been pursuing the conservation of biodiversity since 2001 by creating green networks in urban residential districts under its Gohon no ki (“five trees”) indigenous landscaping concept. Together with the University of the Ryukyus1 , the company has analyzed the outcome of the Gohon no ki Project that it has implemented with 1 million customer households2 over the space of 20 years, and has designed the world’s first mechanism for quantitatively evaluating urban biodiversity. It has published this qualitative evaluation mechanism today as a nature-positive methodology for promoting the conservation of biodiversity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005350/en/
The Gohon no ki Project
Since the 1970s, incessant urban development has dramatically reduced the amount of habitat available for flora and fauna in our cities. Sekisui House launched its Gohon no ki Project in 2001 as an initiative to conserve biodiversity through the eco-friendly landscaping and greening of the gardens of its customers. Based on the concept of planting five locally native trees, three for birds and two for butterflies, the Gohon no ki Project proposes greening gardens and local communities with native tree species suited to the local climate and benevolent to birds, butterflies, and other local fauna. The project takes its lead from garden landscaping modeled on traditional Japanese satoyama (which translates roughly as “village woodland”).
In the 20 years from 2001 up to 2020, more than 17 million trees have been planted under the project. The company has also promoted urban greening throughout Japan by incorporating the Gohon no ki concept into its planning of green spaces in its condominium and community development initiatives.
Quantitative evaluation of biodiversity
Sekisui House has since 2019 been working with the Kubota Laboratory, Faculty of Science, University of the Ryukyus, and Think Nature Inc. to quantitatively evaluate the contribution of this network-type greening to urban biodiversity. Based on the Japan Biodiversity Mapping Project (J-BMP)3 managed and operated by Think Nature Inc., a company established by Professor Yasuhiro Kubota, the partners have analyzed the data on tree number, species, and location accumulated over the 20 years of the Sekisui House Gohon no ki Project to quantitatively evaluate the effectiveness of the project in conserving and restoring biodiversity.
This quantitative evaluation revealed the following benefits for biodiversity from planting native tree species in line with the Gohon no ki Project as opposed to planting conventional horticultural and exotic species in gardens in urban areas where biodiversity has declined significantly (Japan’s three major metropolitan areas).4
- The number of native tree species in each region—the foundation of regional biodiversity—has increased tenfold.
- The number of bird species that residential districts can attract has doubled.
- The number of butterfly species that residential districts can attract has increased fivefold.
- Biodiversity in the three metropolitan areas has recovered to 30% of the level of 1977 for which the first trustworthy biodiversity related data exists.
This is the world’s first mechanism for quantitatively evaluating urban biodiversity and its application to an actual case. The disclosure of numerical data enables biodiversity to be expressed in terms of financial value, thereby providing a means for visualizing private sector contribution to biodiversity.
Nature-positive methodology
In recent years, increasing efforts are being made to conserve biodiversity. In June of this year, the Taskforce on Nature-related Financial Disclosures (TNFD) was launched, and in October, the 15th Conference of the Parties to the Convention on Biological Diversity (COP15) was held. In Japan too, discussion has begun in earnest on other effective area-based conservation measures (OECMs) for enlisting the support of the private sector to drive urban greening.
In this societal context, Sekisui House is making its 20-year biodiversity conservation initiative available to the public as a nature-positive methodology. The Gohon no ki Project’s nature-positive methodology represents a means for expressing urban biodiversity. Sekisui House is making this methodology available to the general public with the aim of raising awareness and enabling its store of knowledge and expertise to be utilized by others to promote greening and contribute to the conservation of biodiversity.
Nature-positive methodology website
https://www.sekisuihouse.co.jp/gohon_sp/method/
Predicted benefits
Based on joint review of available data, Sekisui House and its partners set the number of tree, bird, and butterfly species, diversity index, and number of individual trees, birds, and butterflies in 1977 as 100%, and using 2000, the year before the Gohon no ki Project was launched, as the base year, simulated change up to 2070 in Japan’s three largest metropolitan areas (Kanto, Kinki and Chukyo) that have suffered the greatest decline in biodiversity. This simulation indicated that planting native tree species that are likely to benefit local fauna (the Gohon no ki concept) compared to 2000, the year before the launch of the Gohon no ki Project, would enable biodiversity to recover to 37.4% of 1977 levels by 2030 (target year for conservation of biodiversity internationally), 40.9% by 2050, and 41.9% by 2070.
If the Gohon no ki concept of planting native trees were applied to 30% of all newly constructed properties in Japan moving forward, urban biodiversity is predicted to rise to 84.6% of 1977 levels. Sekisui House believes that this indicates that if the private sector works with the general public, the decline in biodiversity can be reversed to achieve the goal of post-2020 biodiversity recovery that is the theme of COP15, and that its Gohon no ki concept can contribute to this goal.
We've received comments of endorsement from the following people. For more details, please refer to the attached document or the original news release
via your browser.
https://www.sekisuihouse.co.jp/english/company/release/topics_2021/20211126_en/
- Mr. Makoto Haraguchi, Fellow, MS & AD InterRisk Research Institute and Sustainability Section SVP for TNFD, MS & AD Insurance Group Holdings
- Mr. Teppei Dohke, Executive Secretary General of the Japan Committee for the International Union for Conservation of Nature
- Ms. Mariko Kawaguchi, Specially Appointed Professor, Rikkyo University / Executive Advisor to CEO, Fuji Oil Holdings Inc.
- Mr. Yasuhiro Kubota, Professor, Faculty of Science, University of the Ryukyus / Representative Director, Think Nature Inc.
1. This is joint research with the Kubota Laboratory, Faculty of Science, University of the Ryukyus.
2. Cumulative number of households built from February 2001 to January 2021 is 1,001,977.
3. Japan Biodiversity Mapping Project (J-BMP) website: https://biodiversity-map.thinknature-japan.com
4. Comparison of continuing to plant conventional garden tree species with planting tree species in line with the Gohon no ki
concept over the 20 years from 2001 to 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005350/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
